The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Challenges of measuring overall survival in elderly patients with MDS
Theo de Witte
Alex Smith
Moshe Mittelman
Mikkael A. Sekeres
Rena BucksteinDuring the MDS Hub Steering Committee meeting held on November 14, 2022, Theo de Witte chaired a discussion on the challenges of measuring overall survival in elderly patients with myelodysplastic syndromes (MDS), with contributions from Rena Buckstein, Moshe Mittelman, Mikkael Sekeres, and Alex Smith.
Challenges of measuring overall survival in elderly patients with MDS
de Witte outlines the differences in overall and relative survival according to iron toxicity, transfusion dose density, and Revised International Prognostic Scoring System risk group. Moving forward, De Witte goes on to describe the causes of death in patients with lower-risk MDS, including the substantial proportion of patients that die from competing causes, and the committee debates the difficulties in determining whether cause of death is related to MDS. They also discuss the use of relative survival as a parameter when identifying competing reasons for the cause of death in elderly patients with MDS, and how this outcome could be used alongside other clinical data to better elucidate the impact of MDS on mortality.